Description of Business - Schedule of Segment Revenues and Significant Expense Categories in Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenues:
Total revenues	$ 348,966	$ 285,504	$ 198,962
Less significant segment expenses (income):
Cost of goods sold - commercial, excluding amortization of acquired intangible assets	26,800	17,429	20,863
Amortization of intangible assets	3,973
Research and development	66,348	45,893	31,283
Interest income, net	(8,053)	(12,615)	(6,154)
Consolidated net income (loss)	5,863	27,588	(11,938)
Other Significant Segment
Revenues:
Total revenues	348,966	285,504	198,962
Less significant segment expenses (income):
Cost of goods sold - commercial, excluding amortization of acquired intangible assets	26,800	17,429	20,863
Cost of revenue - collaborations and services	61,160	59,173	41,908
Amortization of intangible assets	3,973
Research and development	66,348	45,893	31,283
Selling	64,015	49,191	51,776
General and administrative	80,120	45,138	42,538
Interest income, net	(8,053)	(12,615)	(6,154)
Interest expense, net	38,029	37,981	25,161
Impairment of available-for-sale investment	6,409	(1,550)	(170)
Loss on settlement of debt		20,444
Other	4,302	(3,168)	3,695
Consolidated net income (loss)	5,863	27,588	(11,938)
Afrezza | Other Significant Segment
Revenues:
Total revenues	74,587	64,041	54,914
Developed technology - on-body infusor | Other Significant Segment
Revenues:
Total revenues	16,372	18,288	19,115
Furoscix | Other Significant Segment
Revenues:
Total revenues	23,178
Collaborations and services
Revenues:
Total revenues	106,713	100,840	52,954
Less significant segment expenses (income):
Cost of revenue - collaborations and services	61,160	59,173	41,908
Collaborations and services | Other Significant Segment
Revenues:
Total revenues	106,713	100,840	52,954
Royalties
Revenues:
Total revenues	128,116	102,335	71,979
Royalties | Other Significant Segment
Revenues:
Total revenues	$ 128,116	$ 102,335	$ 71,979